| ★ | IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | |
| 6 | Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 88 |
| 8 | ERN ReCONNET: the New 2026 Webinar Series | | 630 | — | 88 |
| 3 | Recent advances in the treatment of inflammatory myopathies | | 618 | — | 89 |
| 14 | CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 87 |
| 9 | What is the added value of triple therapy in lupus nephritis? | | 438 | — | 88 |
| 11 | Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 87 |
| 1 | Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 93 |
| 4 | ERN ReCONNET video to launch the RARE DISEASES AWARENESS MONTH 2024! | | 360 | — | 89 |
| 17 | How to explain the antiphospholipid profile to my patients? | | 300 | — | 87 |
| 2 | Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025? | | 285 | — | 90 |
| 18 | Countdown to Rare Disease Day 2026! | National Organization for Rare Disorders (NORD) @raredisorders | 277 | Estados Unidos | 87 |
| 20 | Systemic sclerosis and pregnancy, a 2026 update | | 257 | — | 87 |
| 12 | RDI Public Webinar: Towards a World Health Assembly Resolution on Rare Diseases 2025 | Rare Diseases International @rarediseasesinternational3378 | 208 | — | 87 |
| 7 | Imaging in Relapsing Polychondritis (RP) | | 171 | — | 88 |
| 16 | ERN ReCONNET New Sjögren’s Syndrome (SS) Disease Coordinator: Prof. Gaetane Nocturne (EN) | | 133 | — | 87 |
| 19 | ERN ReCONNET New Sjögren’s Syndrome (SS) Disease Coordinator: Prof. Gaetane Nocturne (FR) | | 99 | — | 87 |
| 10 | Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 88 |
| 5 | Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies | | 64 | — | 89 |
| 15 | Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 87 |
| 13 | Genetic Testing in the Era of NGS: Lessons from the Hereditary Connective Tissue Disorders | | 35 | — | 87 |